Literature DB >> 23454863

Curing HIV: lessons from cancer therapy.

Ronald Mitsuyasu1.   

Abstract

PURPOSE OF REVIEW: Interest in finding a potential 'cure' for HIV has taken on greater interest and urgency since the report of an individual who underwent allogeneic stem cell transplant from a CCR5 delta 32 homozygote donor after high-dose chemotherapy for acute myeloid leukemia. The potential role of cancer chemotherapy and other cancer-directed treatment approaches is discussed in the context of their potential role in helping to eliminate HIV from the infected host. RECENT
FINDINGS: Cancer chemotherapy and other cancer-targeted agents have been used successfully in treating a variety of malignancies in both HIV-infected and HIV-uninfected individuals. Lessons learned from these strategies may be of importance in helping to define more effective ways of controlling and eliminating HIV as well. Application of these anticancer strategies to patients with HIV are beginning to be explored and may help determine their potential usefulness in this disease as well.
SUMMARY: Although cytotoxic chemotherapy is a crude and not particularly effective way of removing HIV latently infected cells and tissue reservoirs, several new approaches to targeting and controlling cancer proliferation may be of value in HIV cure research and may one day help to end this disease.

Entities:  

Mesh:

Year:  2013        PMID: 23454863      PMCID: PMC3789644          DOI: 10.1097/COH.0b013e32835ef0a1

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  41 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 4.  Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Authors:  Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

5.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Authors:  Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

6.  Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.

Authors:  Anthony R Cillo; Amrita Krishnan; Ronald T Mitsuyasu; Deborah K McMahon; Shirley Li; John J Rossi; John A Zaia; John W Mellors
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

7.  The effect of anti-neoplastic drugs on murine acquired immunodeficiency syndrome.

Authors:  C Simard; P Jolicoeur
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

8.  The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.

Authors:  Alain Lafeuillade; Gilles Hittinger; Stéphane Chadapaud; Serge Maillefet; Alain Rieu; Cécile Poggi
Journal:  HIV Clin Trials       Date:  2002 Jul-Aug

9.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

Authors:  P Ashorn; B Moss; J N Weinstein; V K Chaudhary; D J FitzGerald; I Pastan; E A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 12.779

View more
  7 in total

1.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 2.  Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.

Authors:  Barna Dey; Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 3.  Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Authors:  Mark N Polizzotto; Grace Chen; Randall L Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

4.  Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Authors:  Paul W Denton; Julie M Long; Stephen W Wietgrefe; Craig Sykes; Rae Ann Spagnuolo; Olivia D Snyder; Katherine Perkey; Nancie M Archin; Shailesh K Choudhary; Kuo Yang; Michael G Hudgens; Ira Pastan; Ashley T Haase; Angela D Kashuba; Edward A Berger; David M Margolis; J Victor Garcia
Journal:  PLoS Pathog       Date:  2014-01-09       Impact factor: 6.823

Review 5.  HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Authors:  Angela Battistini; Marco Sgarbanti
Journal:  Viruses       Date:  2014-04-14       Impact factor: 5.048

Review 6.  Lessons Learned From Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?

Authors:  V Kalidasan; Kumitaa Theva Das
Journal:  Front Microbiol       Date:  2020-01-31       Impact factor: 5.640

7.  Identifying a Minor Histocompatibility Antigen in Mauritian Cynomolgus Macaques Encoded by APOBEC3C.

Authors:  Jason T Weinfurter; Michael E Graham; Adam J Ericsen; Lea M Matschke; Sian Llewellyn-Lacey; David A Price; Roger W Wiseman; Matthew R Reynolds
Journal:  Front Immunol       Date:  2020-10-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.